Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus SYNOPHYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus SYNOPHYLATE.
BRONKAID MIST vs SYNOPHYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
SYNOPHYLATE is a bronchodilator that inhibits phosphodiesterase, leading to increased intracellular cAMP. It also acts as an adenosine receptor antagonist and enhances histone deacetylase activity, causing relaxation of bronchial smooth muscle.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
400-800 mg orally every 6-8 hours; maximum 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life is 3-4 hours in healthy adults, but can be prolonged to 6-8 hours in neonates, cirrhotic patients, or those with heart failure. Clinical context: Requires frequent dosing or extended-release formulations to maintain therapeutic levels.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; hepatic metabolism via CYP450 (primarily CYP1A2, CYP3A4) accounts for the remainder. Biliary/fecal excretion of metabolites is minor (<5%).
Category C
Category C
Bronchodilator
Bronchodilator